The Sputnik Light, a Russian single-component coronavirus vaccine (the first component of the Sputnik V vaccine), has shown a high safety record and 93.5% efficacy in a vaccination in Paraguay, Russian Direct Investment Fund (RDIF) said.
The RDIF, a sovereign fund in the Russian Federation, announces information from the Paraguay’s Ministry of Health demonstrating high safety performance of the single-component vaccine Sputnik Light and 93.5% effectiveness during mass vaccination in the country.
The efficacy calculation, the Fund said, was based on data analysis from 320,000 people who had been vaccinated with Sputnik Light as of July 30, 2021.
Statistics on the use of Sputnik Light in Paraguay demonstrate the vaccine’s high safety profile: for example, the RDIF noted that there have been no vaccine-related serious adverse events, no cases of death, no cases of cerebral venous thrombosis (CVT), Guillain-Barré syndrome, increased capillary permeability syndrome, etc.
RDIF was the first in the world to initiate joint research on the combination of the first component of Sputnik V with foreign drugs. Preliminary results of a clinical trial on the combined use of the Sputnik Light vaccine and AstraZeneca product in Azerbaijan demonstrate the absence of serious adverse events and cases of disease.